Odaia closes $15M Series C led by Monograph Capital, a University of Toronto spinout
Odaia, a Boston and Toronto company that sells predictive commercial intelligence software to pharmaceutical companies, has closed a US$15 million Series C. BetaKit reports the round at about C$21 million. Monograph Capital led the financing, and PHM, the US health media agency owned by Publicis Groupe, joined as a strategic investor. The press release is dated November 17, 2026. BetaKit names Odaia, not Monograph, as the University of Toronto spinout.
Returning investors took part. Series A backers BDC Capital, Flint Capital, Innospark Ventures and Graphite Ventures came back, as did Series B investors Threshold Ventures and Wittington Ventures. Monograph had co-led the $25 million Series B in 2023 with Threshold. The round also carries a platform agreement that makes PHM Odaia's exclusive agency partner in the US, so PHM can bring the software to its pharma clients for coordinating digital media and field-sales outreach.
Funds will go toward expanding within existing enterprise pharma accounts and developing the platform. The product blends patient, healthcare professional, digital engagement and field-sales signals to flag physicians whose patients may need a therapy months before a diagnosis appears in available data. A Dealroom summary lists Novo Nordisk, GSK and Ardelyx among more than 40 brands onboarded. Valuation, revenue and total capital raised were not disclosed.
Why it matters
For founders selling AI into life sciences, the round shows that a commercial contract can arrive alongside an equity round. A strategic partner that carries the product to its own clients can shorten a sales cycle that would otherwise start from zero. That also means part of the revenue path depends on another company's priorities, so teams building for pharma should weigh that trade-off early.
For investors, the deal shows that agency distribution can be a financing argument in itself. Founders selling through agencies should expect buyers to ask for proof of outcomes before signing multi-year contracts. With no revenue disclosed, investors are judging traction mainly from the partnership terms rather than reported sales.
Key points
- 1Odaia's Series C totals US$15 million, which BetaKit converts to about C$21 million.
- 2Monograph Capital led the Series C, with PHM participating as a strategic investor.
- 3PHM became Odaia's exclusive agency partner in the United States under a commercial platform agreement.
- 4Six returning investors from the Series A and Series B rounds took part in the Series C.
- 5Odaia did not disclose a valuation, revenue, or total capital raised to date.